ANDA 218617, held by Aurobindo Pharma Ltd. Tafamidis Meglumine.
As of Nov 15, 2026, ANDA 218617 (Tafamidis Meglumine), held by Aurobindo Pharma Ltd, was first approved by FDA on Nov 6, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 6, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tafamidis Meglumine20MG ยท capsule;oral | Tafamidis Meglumine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters